Victory Capital Management
BCAX

Victory Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Victory Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Hold
10,070
– – ﹤0.01% 2198
2025
Q4 		$169K Buy
10,070
+160
+2% +$2.73K ﹤0.01% 2225
2025
Q3 		$156K Hold
9,910
– – ﹤0.01% 2248
2025
Q2 		$92.1K Sell
9,910
-24,520
-71% -$292K ﹤0.01% 2334
2025
Q1 		$449K Buy
+34,430
New +$457K ﹤0.01% 2058

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Victory Capital Management's BCAX Position: Q1 2026 in Review

Victory Capital Management held its Bicara Therapeutics (BCAX) position steady in Q1 2026 at 10,070 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #2198.

Victory Capital Management first reported a position in BCAX in Q1 2025 and has held it in 5 quarters since. The position peaked at $449K in Q1 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Victory Capital Management held 10,070 shares of Bicara Therapeutics worth $200K as of Q1 2026.
  • Victory Capital Management left its Bicara Therapeutics share count unchanged in Q1 2026.
  • Bicara Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2198 holding.
  • Victory Capital Management first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Victory Capital Management's Bicara Therapeutics position peaked at $449K in Q1 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.